Immediate Impact
58 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Works of Thomas J. Prior being referenced
A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
2022
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force
2016 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Thomas J. Prior | 133 | 98 | 440 | 185 | 11 | 1.0k | |
| Laura Ginnelly | 50 | 71 | 497 | 262 | 13 | 1.2k | |
| Ellen M. Janssen | 126 | 32 | 401 | 283 | 50 | 1.1k | |
| Fatima Mili | 69 | 82 | 147 | 278 | 19 | 1.1k | |
| Hanane Khoury | 125 | 54 | 483 | 200 | 36 | 1.2k | |
| Ateesha F. Mohamed | 196 | 38 | 532 | 188 | 64 | 1.3k | |
| Jonathan Tosh | 82 | 192 | 526 | 236 | 36 | 1.3k | |
| Thomas R. Oliver | 120 | 54 | 283 | 400 | 38 | 1.0k | |
| Adrian Gheorghe | 88 | 26 | 319 | 245 | 31 | 1.2k | |
| C Jenkinson | 129 | 36 | 202 | 533 | 28 | 1.4k | |
| Helen Clark | 101 | 57 | 176 | 136 | 36 | 917 |
All Works
Login with ORCID to disown or claim papers
Loading papers...